In terms of therapy, to date, there are clinical trials with HSP105/110 peptide vaccine—the preliminary results suggest that the vaccine could induce immunological effects and improve prognosis in patients with CRC or esophageal cancer [78]. Here, HSPH1 is linked to colorectal carcinoma.